This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuance Buys New York Software Firm

SAN FRANCISCO -- Continuing to consolidate the software market for speech recognition, Nuance (NUAN - Get Report) said Tuesday it acquired Commissure, a New York-based developer.

Commissure develops speech recognition and other data-capture software specifically for medical imaging labs. The deal enables Nuance to provide a fuller suite of software for the radiology market.

Friedman Billings analyst Daniel Ives estimated that Nuance paid $4 million for the company. But the deal is Nuance's sixth in 2007 and brings its total acquisition outlay to between $775 million and $800 million, Ives said in an interview. The company is using acquisitions to expand its product portfolio, rather than to buy market share.

Nuance is by far the leader in voice-recognition software, with nearly 66% of the market in 2006, according to Gartner. The company's nearest competitor, LumenVox, has 7.8%, while IBM (IBM - Get Report) has 6.6% and Microsoft (MSFT - Get Report) has 3.2%.

Although a small transaction that should have a "negligible financial impact," the deal beefs up Nuance's healthcare product suite, Ives said in a research note Tuesday.

The acquisition will enable Burlington, Mass.-based Nuance to speed its transcription process while reducing costs, "hitting a major pain point of current healthcare customers worldwide," Ives wrote. FBR makes a market in shares of Nuance.

Shares of Nuance were recently down 7 cents, or 0.4%, to $19.32. The stock trades at 25 times 2008 expected EPS of 78 cents.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
IBM $172.22 0.00%
MSFT $46.90 0.00%
NUAN $16.94 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs